Journal of Preventive Medicine

An Updated Review on the Therapeutic Agents for Coronavirus Disease 2019

Coronavirus disease 2019 (COVID-19) emerged at the end of 2019 in Wuhan, China, and spread rapidly over other regions of the world. The pandemic coronavirus disease 19 (COVID-19) was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no approved vaccine along with therapeutic agents available for the treatment of COVID-19. This review mainly focused on the most common and local drugs for the treatment of COVID-19. These therapeutic drugs include antiviral agents (Remdesivir, Lopinavir/Ritonavir, Umifenovir, Favipiravir, Oseltamivir), miscellaneous agents and therapies (Angiotensin-Converting Enzyme Inhibitors (ACEI), Non-steroidal anti-inflammatory drugs (NSAID), Colchicine, Convalescent Plasma therapy (CP therapy), Nitazoxanide), and other agents (Azithromycin, Vitamin C (Ascorbic acid), Corticosteroids and Dexamethasone), and Traditional Chinese Medicines. The material of this review is gathered from different research papers published on the aforementioned drugs for their potential use against COVID-19. However, none have enough evidence and requires more clinical trials.

Author(s):

Muhammad Siraj, Maham Khan, Sadia Khan

Abstract | Full-Text | PDF

Share this